Celldex's prurigo nodularis data for barzolvolimab lands with itch-relief bar set at Week 12
The Phase 2 trial completed enrollment at target and stands active but not recruiting, setting up a placebo-controlled readout on worst-itch relief with no direct KIT-targeted precedent in this disease.
Executive Summary
- Celldex has guided topline data from its placebo-controlled Phase 2 prurigo nodularis trial toward the second half of 2026, testing whether barzolvolimab's mast-cell mechanism extends beyond urticaria into a separate itch-driven skin disease.
- The trial completed enrollment at its target and shifted to a non-recruiting status on schedule, leaving execution risk low heading into the readout.
- No KIT-targeted therapy has been tested against prurigo nodularis before, so this trial will be the first test of whether blocking the KIT receptor eases the disease's nodular itch, informed by barzolvolimab's own positive urticaria results.
- A Week 12 itch result that clears the trial's own four-point improvement threshold against placebo would extend the drug's validated mechanism into a second dermatologic indication ahead of any registrational commitment there.
The catalyst
Celldex has guided topline data from its Phase 2 study of barzolvolimab in prurigo nodularis to the second half of 2026, most recently narrowing that guidance to the third quarter in a May 2026 update. The trial, NCT06366750, is a randomized, placebo-controlled study testing barzolvolimab against placebo in adults with prurigo nodularis, a chronic nodular itching condition. Its primary endpoint measures the proportion of patients achieving at least a four-point improvement in the Worst Itch Numeric Rating Scale (WI-NRS), a patient-reported itch-severity score, from baseline to Week 12. Celldex+1Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNov 10, 2025A Study of Barzolvolimab in Patients With Prurigo NodularisNCT06366750
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial footing
The trial enrolled 140 patients against its own target of 140, and moved from Recruiting to Active, not recruiting in December 2025, alongside an enrollment update from 120 to 140 patients. That enrollment change sits within the routine band the operational model uses to flag outsized shifts, which starts at 20% or more; a target-to-target completion at 140 patients is not a shift of that kind. The trial's primary completion date moved from January 2026 to June 2026, a change registered alongside the enrollment and status updates in the same December 2025 filing. NCT06366750A Study of Barzolvolimab in Patients With Prurigo NodularisNCT06366750
The mechanism test
Barzolvolimab binds the KIT receptor, a tyrosine kinase that controls mast cell survival and activity, and Celldex has reported that the drug met all primary and secondary endpoints in its Phase 2 chronic spontaneous urticaria trial and showed sustained efficacy in cold urticaria and symptomatic dermographism. No other KIT-targeted therapy has been tested against prurigo nodularis, and the competitive field in this indication is dominated by other mechanisms: Incyte's povorcitinib (a JAK1 inhibitor), Galderma's nemolizumab, and Sanofi's dupilumab all have Phase 3 programs underway in the same disease. Barzolvolimab is developed against a different target than any of those programs, making this trial the first clinical test of whether KIT-directed mast cell suppression eases prurigo nodularis specifically, rather than a race against a mechanism already validated there. CelldexCelldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNov 10, 2025
What the readout will show
The trial's design, a randomized, placebo-controlled, double-blind study with a prespecified four-point WI-NRS threshold at Week 12, is built to produce a decision-grade signal on efficacy rather than a hypothesis-generating one. Because no KIT-targeted precedent exists in this disease, the informative comparison is not against a competitor's threshold but against the effect size barzolvolimab already produced in chronic urticaria, where Celldex has characterized the CSU result as statistically significant and clinically meaningful. A Week 12 result that clears the trial's own four-point bar against placebo would be the finding that extends the mechanism; a result drifting toward the placebo response rate would be the one that narrows it to urticaria. CelldexCelldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNov 10, 2025
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.